Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment

E W de Bekker-Grob, M C J Bliemer, B Donkers, M-L Essink-Bot, I J Korfage, M J Roobol, C H Bangma, E W Steyerberg, E W de Bekker-Grob, M C J Bliemer, B Donkers, M-L Essink-Bot, I J Korfage, M J Roobol, C H Bangma, E W Steyerberg

Abstract

Background: Patients' preferences are important for shared decision making. Therefore, we investigated patients' and urologists' preferences for treatment alternatives for early prostate cancer (PC).

Methods: A discrete choice experiment was conducted among 150 patients who were waiting for their biopsy results, and 150 urologists. Regression analysis was used to determine patients' and urologists' stated preferences using scenarios based on PC treatment modality (radiotherapy, surgery, and active surveillance (AS)), and risks of urinary incontinence and erectile dysfunction.

Results: The response rate was 110 out of 150 (73%) for patients and 50 out of 150 (33%) for urologists. Risk of urinary incontinence was an important determinant of both patients' and urologists' stated preferences for PC treatment (P<0.05). Treatment modality also influenced patients' stated preferences (P<0.05), whereas the risk of erectile dysfunction due to radiotherapy was mainly important to urologists (P<0.05). Both patients and urologists preferred AS to radical treatment, with the exception of patients with anxious/depressed feelings who preferred radical treatment to AS.

Conclusion: Although patients and urologists generally may prefer similar treatments for PC, they showed different trade-offs between various specific treatment aspects. This implies that urologists need to be aware of potential differences compared with the patient's perspective on treatment decisions in shared decision making on PC treatment.

References

    1. Aning JJ, Wassersug RJ, Goldenberg SL. Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Curr Oncol. 2012;19:S37–S44.
    1. Ashcroft DM, Seston E, Griffiths CE. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol. 2006;155:1236–1241.
    1. Berchi C, Dupuis JM, Launoy G. The reasons of general practitioners for promoting colorectal cancer mass screening in France. Eur J Health Econ. 2006;7:91–98.
    1. Bishop AJ, Marteau TM, Armstrong D, Chitty LS, Longworth L, Buxton MJ, Berlin C. Women and health care professionals' preferences for Down's syndrome screening tests: a conjoint analysis study. BJOG. 2004;111:775–779.
    1. Damber JE, Khatami A. Surgical treatment of localized prostate cancer. Acta Oncol. 2005;44:599–604.
    1. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Koes BW, Steyerberg EW. Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment. Pharmacoeconomics. 2009;27:211–219.
    1. de Bekker-Grob EW, Hol L, Donkers B, van Dam L, Habbema JD, van Leerdam ME, Kuipers EJ, Essink-Bot ML, Steyerberg EW. Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. Value Health. 2010;13:315–323.
    1. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145–172.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108.
    1. Emberton M. Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. Int J Clin Pract. 2010;64:1425–1435.
    1. Gillitzer R, Thuroff JW. Technical advances in radical retropubic prostatectomy techniques for avoiding complications. Part II: vesico-urethral anastomosis and nerve-sparing prostatectomy. BJU Int. 2003;92:178–184.
    1. Hall J, Fiebig DG, King MT, Hossain I, Louviere JJ. What influences participation in genetic carrier testing? Results from a discrete choice experiment. J Health Econ. 2006;25:520–537.
    1. Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge University Press: Cambridge, UK; 2005.
    1. Kim SI, Kang JY, Lee HW, Seong do H, Cho JS. A survey conducted on patients' and urologists' perceptions of benign prostatic hyperplasia. Urol Int. 2011;86:278–283.
    1. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol. 2006;7:355–362.
    1. Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, Schroder FH, de Koning HJ. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer. 2005;116:291–296.
    1. Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics. 2008;26:661–677.
    1. Lee A, Gin T, Lau AS, Ng FF. A comparison of patients' and health care professionals' preferences for symptoms during immediate postoperative recovery and the management of postoperative nausea and vomiting. Anesth Analg. 2005;100:87–93.
    1. Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia. 2005;11:589–597.
    1. Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians. Qual Health Care. 2001;10 (Suppl 1:i39–i43.
    1. Pearmain D, Swanson J, Kroes E, Bradley M. Stated Preferences Techniques: A Guide To Practice. The Hague, Steer Davis Gleave and Hague Consulting Group: Hagues, The Netherlands; 1991.
    1. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol. 2008;179:S40–S44.
    1. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358–1367.
    1. Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011;29:3–9.
    1. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3–13.
    1. Roobol MJ, Schroder FH. European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int. 2003;92 (Suppl 2:117–122.
    1. Ryan M. Discrete choice experiments in health care. BMJ. 2004;328:360–361.
    1. Salkeld G, Solomon M, Butow P, Short L. Discrete-choice experiment to measure patient preferences for the surgical management of colorectal cancer. Br J Surg. 2005;92:742–747.
    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328.
    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–990.
    1. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283:354–360.
    1. Street DJ, Burgess L, Louviere JJ. Constructing optimal and nearly optimal stated choice experiments. Intern J Res Marketing. 2005;22:459–470.
    1. Swait J, Louviere J. The role of the scale parameter in the estimation and comparison of multinomial logit models. J Marketing Res. 1993;30:305–314.
    1. Szeinbach SL, Harpe SE, Williams PB, Elhefni H. Testing for allergic disease: parameters considered and test value. BMC Fam Pract. 2008;9:47.
    1. Train KE. Discrete Choice Methods With Simulations. Cambridge University Press: Cambridge, UK; 2003.
    1. van den Bergh RC, Essink-Bot ML, Roobol MJ, Schroder FH, Bangma CH, Steyerberg EW. Do anxiety and distress increase during active surveillance for low risk prostate cancer. J Urol. 2010;183:1786–1791.
    1. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, Leer JW. Do patients with localized prostate cancer treatment really want more aggressive treatment. J Clin Oncol. 2006;24:4581–4586.
    1. van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int. 2013;111:564–573.
    1. Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer. 2006;106:1865–1874.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi